Founded as a spin-out from the National University of Singapore (NUS), INEX Innovate is Asia's first healthcare technology company for women.

We focus on Innovations in Molecular Diagnostics— ideating, developing and translating new technologies to address unmet needs in women’s and fetal health. Our vision is to make its technologies accessible to women across Asia and around the world, and to give women and mothers greater certainty and confidence in diagnostic testing by pushing the boundaries of science.

INEX currently has in excess of forty-seven key patents, nine trademarks, and exclusive licenses for Next Generation Sequencing Technology and Non Invasive Prenatal Testing from Global Centres of Medical Excellence. We are backed by institutional and government shareholders including Enterprise Singapore, Genting Berhad and PriceWaterhouseCoopers.


Together with our partners, we are dedicated to applying our R&D capabilities to put our patient’s first. We develop solutions to today’s most prevalent women’s health challenges while ensuring equity and access to products that change their approach to healthcare.


In 2020 the company was a finalist in the Business Transformation of the Year award category at the British Chamber of Commerce Singapore Annual Business Awards in recognition of its efforts in launching new technologies and pivoting towards COVID-19 testing to support Singapore’s battle against the COVID-19 pandemic.

In 2021 was recipient of the prestigious Frost & Sullivan ‘Singapore Clinical Laboratories in Women’s Health Entrepreneurial Company of the Year Award’.